FIMECS Presents at Targeted Protein Degradation Forum in Japan (22-23 August)
News release Download PDF
Kanagawa, Japan, 18 July 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Kanae Gamo, Vice President of Biology, will make a presentation at Targeted Protein Degradation Forum in Japan (22-23 August, 2019 in Fujisawa, Japan).
For more information:
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno, CFO and VP of Corporate Development
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan